Lisa Nottebaum

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies

Bhavatarini Vangamudi, Thomas A. Paul, Parantu K. Shah et al. · Cancer Research · 2015 · 270 citations

Life Sciences, Molecular Biology, Oncology +13

Discovery of the Potent and Selective M1 PAM-Agonist<i>N</i>-[(3<i>R</i>,4<i>S</i>)-3-Hydroxytetrahydro-2<i>H</i>-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects

Jennifer E. Davoren, Che‐Wah Lee, Michelle R. Garnsey et al. · Journal of Medicinal Chemistry · 2016 · 83 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Design and Synthesis of γ- and δ-Lactam M₁ Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M₁-Selective PAM with Weak Agonist Activity

Jennifer E. Davoren, Michelle R. Garnsey, Betty Pettersen et al. · Journal of Medicinal Chemistry · 2017 · 58 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Role of the GLT‐1 subtype of glutamate transporter in glutamate homeostasis: the GLT‐1‐preferring inhibitor WAY‐855 produces marginal neurotoxicity in the rat hippocampus

Julie V. Selkirk, Lisa Nottebaum, Alicia M. Vana et al. · European Journal of Neuroscience · 2005 · 36 citations

Life Sciences, Neurobiology, Neuroscience +15

Identification of differential melanocortin 4 receptor agonist profiles at natively expressed receptors in rat cortical astrocytes and recombinantly expressed receptors in human embryonic kidney cells

Julie V. Selkirk, Lisa Nottebaum, J. Lee et al. · Neuropharmacology · 2006 · 34 citations

Life Sciences, Neuroscience, Pharmacology +12